183 related articles for article (PubMed ID: 28931525)
1. Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
Zurli V; Wimmer G; Cattaneo F; Candi V; Cencini E; Gozzetti A; Raspadori D; Campoccia G; Sanseviero F; Bocchia M; Baldari CT; Kabanova A
Blood; 2017 Nov; 130(18):2006-2017. PubMed ID: 28931525
[TBL] [Abstract][Full Text] [Related]
2. Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia.
Colovai AI; Tsao L; Wang S; Lin H; Wang C; Seki T; Fisher JG; Menes M; Bhagat G; Alobeid B; Suciu-Foca N
Cytometry B Clin Cytom; 2007 Sep; 72(5):354-62. PubMed ID: 17266150
[TBL] [Abstract][Full Text] [Related]
3. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.
Kawauchi K; Ogasawara T; Yasuyama M
Int J Hematol; 2002 Jun; 75(5):508-13. PubMed ID: 12095152
[TBL] [Abstract][Full Text] [Related]
4. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.
Capitani N; Lucherini OM; Sozzi E; Ferro M; Giommoni N; Finetti F; De Falco G; Cencini E; Raspadori D; Pelicci PG; Lauria F; Forconi F; Baldari CT
Blood; 2010 May; 115(18):3726-36. PubMed ID: 20061561
[TBL] [Abstract][Full Text] [Related]
5. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Cattaneo F; Patrussi L; Capitani N; Frezzato F; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncotarget; 2016 Aug; 7(35):57086-57098. PubMed ID: 27494881
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.
Suljagic M; Laurenti L; Tarnani M; Alam M; Malek SN; Efremov DG
Leukemia; 2010 Dec; 24(12):2063-71. PubMed ID: 20861921
[TBL] [Abstract][Full Text] [Related]
7. CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.
Liu FT; Giustiniani J; Farren T; Jia L; Bensussan A; Gribben JG; Agrawal SG
Blood; 2010 Apr; 115(15):3079-88. PubMed ID: 20164468
[TBL] [Abstract][Full Text] [Related]
8. The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling.
Gordiienko I; Shlapatska L; Kholodniuk V; Sklyarenko L; Gluzman DF; Clark EA; Sidorenko SP
PLoS One; 2017; 12(10):e0185940. PubMed ID: 28982149
[TBL] [Abstract][Full Text] [Related]
9. A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis.
Vanni F; Lopresti L; Zurli V; Kabanova A; Cattaneo F; Sicuranza A; Gozzetti A; Gemma S; Zisterer DM; Bocchia M; Campiani G; Baldari CT; Butini S; Ulivieri C
Pharmacol Res; 2021 Dec; 174():105965. PubMed ID: 34732370
[TBL] [Abstract][Full Text] [Related]
10. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
[TBL] [Abstract][Full Text] [Related]
11. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia.
Seda V; Vojackova E; Ondrisova L; Kostalova L; Sharma S; Loja T; Mladonicka Pavlasova G; Zicha D; Kudlickova Peskova M; Krivanek J; Liskova K; Kren L; Benes V; Musilova Litzmanova K; Borsky M; Oppelt J; Verner J; Pospisilova S; Brychtova Y; Panovska A; Tan Z; Zhang S; Doubek M; Amruz Cerna K; Mayer J; Mraz M
Blood; 2021 Sep; 138(9):758-772. PubMed ID: 33786575
[TBL] [Abstract][Full Text] [Related]
12. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
von Wenserski L; Schultheiß C; Bolz S; Schliffke S; Simnica D; Willscher E; Gerull H; Wolters-Eisfeld G; Riecken K; Fehse B; Altfeld M; Nollau P; Binder M
Leukemia; 2021 Apr; 35(4):1073-1086. PubMed ID: 32826957
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.
Muzio M; Apollonio B; Scielzo C; Frenquelli M; Vandoni I; Boussiotis V; Caligaris-Cappio F; Ghia P
Blood; 2008 Jul; 112(1):188-95. PubMed ID: 18292287
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.
Bailón E; Ugarte-Berzal E; Amigo-Jiménez I; Van den Steen P; Opdenakker G; García-Marco JA; García-Pardo A
J Leukoc Biol; 2014 Aug; 96(2):185-99. PubMed ID: 25080557
[TBL] [Abstract][Full Text] [Related]
15. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
16. Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.
Hofbauer SW; Piñón JD; Brachtl G; Haginger L; Wang W; Jöhrer K; Tinhofer I; Hartmann TN; Greil R
Cancer Res; 2010 Sep; 70(18):7336-44. PubMed ID: 20823161
[TBL] [Abstract][Full Text] [Related]
17. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
Kohlhaas V; Blakemore SJ; Al-Maarri M; Nickel N; Pal M; Roth A; Hövelmeyer N; Schäfer SC; Knittel G; Lohneis P; Nikolic M; Wiederstein JL; Franitza M; Georgomonolis T; Reinart N; Herling M; Herling C; Hartmann EM; Rosenwald A; Klapper W; Büttner R; Moia R; Rossi D; Boldorini R; Gaidano G; Frenzel LP; Reinhardt HC; Brüning JC; Hallek M; Krüger M; Peifer M; Pallasch CP; Wunderlich FT
Blood; 2021 Feb; 137(5):646-660. PubMed ID: 33538798
[TBL] [Abstract][Full Text] [Related]
18. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
McKenna MK; Noothi SK; Alhakeem SS; Oben KZ; Greene JT; Mani R; Perry KL; Collard JP; Rivas JR; Hildebrandt GC; Fleischman RA; Durbin EB; Byrd JC; Wang C; Muthusamy N; Rangnekar VM; Bondada S
Blood; 2018 Jun; 131(26):2943-2954. PubMed ID: 29695515
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
20. A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients.
Rossi S; Tatangelo V; Dichiara M; Butini S; Gemma S; Brogi S; Pasquini S; Cappello M; Vincenzi F; Varani K; Lopresti L; Malchiodi M; Carrara C; Gozzetti A; Bocchia M; Marotta G; Patrussi L; Carullo G; Baldari CT; Campiani G
Biomed Pharmacother; 2024 May; 174():116537. PubMed ID: 38579402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
